BioSig Technologies Getting Traction with PURE EP ™ System, Could Move Following Listing on the NASDAQ

BioSig Technologies, Inc. (OTCQB: BSGM) is a medical device company developing a proprietary biomedical signal processing technology designed to improve the $4.6 billion electrophysiology (EP) marketplace. BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has been developed to address an unmet need in a large and growing market. The device is designed to record, analyze and display electrocardiogram and Electrograms used in electrophysiology studies and catheter ablation studies.

In the recent past, the company has made noticeable progress in all areas of its business and financial risk profile and hit a critical inflection point that positions it for significant momentum and growth in 2018 and beyond. More recently, the company’ stock has seen strong momentum building up after it announced that the Company had received 510(k) clearances for its first product, PURE EP System, from the U.S. Food and Drug Administration.  As per management, Initial systems have been produced that will support a limited rollout. Also, the company plans to up list to Nasdaq this year.


From a liquidity standpoint, on August 17th, the company announced that it had received final proceeds from an oversubscribed capital raise, totaling approximately $6,000,000. BioSig has now raised approximately $12.5 million in 2018 and received 510(k) clearances from the U.S. Food and Drug Administration for its PURE EP System.

In fact, the oversubscription of funds positions the company well for its strategic growth plan. In addition to strengthening its balance sheet, the finances will assist in moving through the Nasdaq listing process the company began in July, while also providing it with capital to commercialize and launch its PURE EP System that recently received 510(k) FDA clearance.


Key investment highlights and strategic achievements which are instrumental in supporting the timely launch and expansion of the PURE EP™ System in late 2018:

  • Announced FDA 510(k) Clearance for PURE EP System
  • Submitted Application to Uplist to Nasdaq
  • Added to the LD Micro Index
  • Ranked Top 50 for The Silicon Review’s Innovative Companies to Watch in 2018
  • Long-Term Collaboration with Mayo Clinic
  • Core competency in Basic Science, Capital Markets, and Capital Architecture
  • Operates Within Rapidly Emerging Field of Bioelectronic Medicine
  • High-Growth Sector Earns Innovation Premium, Aggressive M&A


Upcoming Catalysts: Analysts tracking to stock believe that BSGM’ significant milestones are right on its doorstep. Also, the company’ experienced management stacks up extremely against potential competition. With multiple catalysts over the near term including FDA approval, Nasdaq up-listing, potential strategic deals, and support from high-quality healthcare institutional investors, BSGM is now at a critical inflection point and is well poised for significant value unlocking for its shareholder value.


Upcoming presentation: The company is selected to present at the third annual MicroCap Leadership Summit, hosted by MicroCapClub, on Friday, September 28, 2018, at the Westin Chicago Northwest Hotel in Itasca, Illinois.


About the PURE EP System: The non-invasive PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. The system is indicated for use under the supervision of licensed healthcare practitioners who are responsible for interpreting the data.  The PURE EP System aims to minimize noise and artifacts and acquire high-fidelity cardiac signals. Improving cardiac signals may potentially increase the diagnostic value of these signals, thereby possibly improving the accuracy and efficiency of the EP studies and related procedures.


Key demand and offtake drivers: PURE EP has the potential to be one of the most significant complementary product to an existing installed base that is dominated by industry leaders. From a growth perspective, the most recent MD&D report shows the global Electrophysiology (EP) market revenues will grow more than 10% annually, from currently just over $4.6 billion to approximately $6 billion by 2020. The Company operates within the rapidly emerging field of bioelectronic medicine, estimated at $3.75 billion in 2017 with the projected annual growth of 14.2%.


BioSig is collaborating with leading EPs from:

Financial results for Three Months Ended June 30, 2018, Compared to Three Months Ended June 30, 2017:

  • Revenues and gross profit: The company had no revenues or cost of goods sold during the three months ended June 2018 and 2017.
  • Net loss: As a result of the foregoing, net loss available to common shareholders for the three months ended June 30, 2018, was $6,047,590 compared to a net loss of $3,101,425 for the three months ended June 30, 2017.
  • Liquidity and financial flexibility – As per management, the company is well capitalized to commercialize and launch its PURE EP System that recently received 510(k) FDA clearance.


Key risk factors and potential stock drivers:

  • Timely DA approval of PURE EP™ technology in late Q2 or early Q3 of 2018 would be a key catalyst over the near term.
  • The company’ business is still at a nascent stage. Even though the company has arranged for the capital to commercialize the PURE EP™. However, timely completion of the project without any time and cost overruns would remain a critical stock sensitivity factor.
  • They may need to finance future cash needs through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements.


Stock Chart:


  • On Wednesday, August 29th, 2018, BSGM was at $2.08, with a volume of 175K shares exchanging hands. Market capitalization is $84.874 million. The current RSI is trending at 38.87
  • At $2.08, shares of BSGM are trading below its 50-day moving average (MA) at $2.36 and above its 200-day moving average (MA) at $1.77.
  • The present support and resistance levels for the stock are at $2.11 & $2.29 respectively.



Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.
This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.
We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.
When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.
17B Disclosure
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.